发明名称 Methods for cancer management targeting Co-029
摘要 The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.
申请公布号 US9487586(B2) 申请公布日期 2016.11.08
申请号 US201514691630 申请日期 2015.04.21
申请人 Institut National de la Santé et de la Recherche Médicale (INSERM);UNIVERSITE DE PARIS XI PARIS SUD 发明人 Rubinstein Eric;Greco Céline;Le Naour François;Boucheix Claude
分类号 A61K39/395;C07K16/28;C07K16/30;C12N15/113;G01N33/574;C12N5/09;A61K39/00 主分类号 A61K39/395
代理机构 Whitham, Curtis & Cook, P.C. 代理人 Whitham, Curtis & Cook, P.C.
主权项 1. A method of treating a Co-029-expressing cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a Co-029 antibody directed against human Co-029, wherein the Co-029 antibody comprises the six complementarity determining region (CDR) sequences of an antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4046 or the six complementarity determining region (CDR) sequences of an antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4047.
地址 Paris FR